2020
DOI: 10.21037/atm-20-941
|View full text |Cite
|
Sign up to set email alerts
|

Narrative review on serous primary peritoneal carcinoma of unknown primary site: four questions to be answered

Abstract: Serous peritoneal papillary carcinoma (SPPC) represents a particular cancer of unknown primary (CUP) entity that arises in the peritoneal surface lining the abdomen and pelvis without a discriminative primary tumor site. In this review, we discuss the validity of SPPC as a distinct entity. Clinically, patients with SPPC are older, have higher parity and later menarche, are more often obese and probably have poorer survival compared to those with primary ovarian cancer. Pathologically, SPPC is more anaplastic a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
11
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 8 publications
(13 citation statements)
references
References 102 publications
2
11
0
Order By: Relevance
“…Therefore, EOC appears to be the ideal candidate for IPDD and remains the best studied indication. In addition, serous primary peritoneal cancer is regarded as sharing many molecular and clinical features with EOC and is treated similarly [65]. The multicenter randomized OVHIPEC trial investigated the additional benefit of cisplatin based HIPEC to cytoreductive surgery (CRS) after neoadjuvant chemotherapy (NACT) in patients with primary EOC who were initially not eligible for CRS due to extensive peritoneal involvement.…”
Section: Ovarian Cancermentioning
confidence: 99%
“…Therefore, EOC appears to be the ideal candidate for IPDD and remains the best studied indication. In addition, serous primary peritoneal cancer is regarded as sharing many molecular and clinical features with EOC and is treated similarly [65]. The multicenter randomized OVHIPEC trial investigated the additional benefit of cisplatin based HIPEC to cytoreductive surgery (CRS) after neoadjuvant chemotherapy (NACT) in patients with primary EOC who were initially not eligible for CRS due to extensive peritoneal involvement.…”
Section: Ovarian Cancermentioning
confidence: 99%
“…[2][3][4][5][6] It includes men with osteoblastic bone metastasis and an elevated level of serum prostate-specific antigen, squamous cell carcinoma of cervical or inguinal lymph nodes, neuroendocrine tumours, women with isolated axillary lymph node metastasis from adenocarcinoma or papillary serous carcinoma of the peritoneal cavity, metastatic melanoma of unknown primary. 2,5,7 The second group comprises the majority of patients, approximately 80%-85%, that cannot be categorized into the favourable prognostic subsets. 8 These patients are resistant to chemotherapy and present a dismal prognosis of 1-3 months only.…”
Section: Introductionmentioning
confidence: 99%
“…2 The first group encompasses a minority of patients, approximately 15%-20%, that presents a constellation of clinical and histological findings suggestive of a primary tumour site. [2][3][4][5][6] It includes men with osteoblastic bone metastasis and an elevated level of serum prostate-specific antigen, squamous cell carcinoma of cervical or inguinal lymph nodes, neuroendocrine tumours, women with isolated axillary lymph node metastasis from adenocarcinoma or papillary serous carcinoma of the peritoneal cavity, metastatic melanoma of unknown primary. 2,5,7 The second group comprises the majority of patients, approximately 80%-85%, that cannot be categorized into the favourable prognostic subsets.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Primary peritoneal carcinoma and advanced OvCa are similar in having peritoneal dissemination and are treated similarly. The recommended treatment integrates aggressive cytoreductive surgery and systemic chemotherapy to remove the macroscopic tumor, eradicate the microscopic residual disease, and control the microscopic metastasis [6]. Even when primary tumors are optimally resected, recurrent tumors frequently emerge in the peritoneum despite the use of conventional platinum-based chemotherapies [7,8] and the estimated median progression-free survival (PFS) is approximately 12-18 months [9].…”
Section: Introductionmentioning
confidence: 99%